RxSight (RXST) News Today

RxSight, Inc. (NASDAQ: RXST) shares are under pressure after a wave of analyst price‐target cuts and newly filed class‐action lawsuits, though the company reported a narrower-than-expected quarterly loss and some brokers still see strong upside.

• Positive Sentiment: RxSight posted a Q2 loss of $0.08 per share, beating the Zacks consensus of a $0.10 loss and surpassing revenue expectations. Zacks: Q2 Loss Beats Estimates
• Positive Sentiment: American Banking & News set a $17.50 price target on RXST, signaling potential upside from current levels. Brokerages Set Price Target at $17.50
• Neutral Sentiment: Q2 2025 earnings call transcript offers detailed commentary on product adoption trends and U.S. market expansion. Earnings Call Transcript
• Negative Sentiment: UBS cut its price target from $16.00 to $8.00 and downgraded RXST to “Neutral.” UBS Price Target Cut
• Negative Sentiment: Stifel Nicolaus lowered its target from $9.00 to $8.00 and placed the stock on “Hold.” Stifel Target Lowered
• Negative Sentiment: Needham & Company cut its price target from $22.00 to $11.00, despite maintaining a “Buy” rating. Needham Price Target Cut
• Negative Sentiment: MarketBeat’s review shows Q2 revenue of $33.6 M missed the $39.8 M consensus and EPS of ($0.08) fell short of the ($0.04) estimate, with margins and ROE turning negative year-over-year. Q2 Financial Results
• Negative Sentiment: At least six securities class actions have been filed against RxSight by firms including Levi & Korsinsky, Rosen Law Firm, Robbins Geller Rudman & Dowd, Glancy Prongay & Murray, The Gross Law Firm and BFA Law, alleging securities-law violations. Class Action Filed